All In Biotech

Drug Trial Radar · NCT04906096

Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL

A Phase 2 Study of Paxalisib (GDC-0084) in Recurrent or Refractory Primary Central Nervous System Lymphoma (PCNSL)

Last checked: Nov 19, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

25

Planned (sponsor's estimate)

Start

Jun 1, 2021

Primary completion

Dec 1, 2026

Study completion Dec 1, 2027

Sponsor

Lead sponsor
Lakshmi Nayak, MDAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Kazia Therapeutics Limited
First posted
May 28, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research study is studying a drug called Paxalisib (GDC-0084) as a possible treatment for primary central nervous system lymphoma (PCNSL)

Conditions

  • Primary Central Nervous System Lymphoma
  • Non-Hodgkin Lymphoma of Extranodal Site

Interventions

  • PAXALISIBDrug

    Each study treatment cycle lasts 28 days, up to 24 months. Oral, daily, dosage per protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Objective Response Rate (ORR)Time frame: Up to 24 Months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Brigham and Women's Hospital

    Boston, Massachusetts · Not yet recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.